Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune… Read more
Raphael Pharmaceutical Inc. (RAPH) - Total Liabilities
Latest total liabilities as of September 2025: $1.27 Million USD
Based on the latest financial reports, Raphael Pharmaceutical Inc. (RAPH) has total liabilities worth $1.27 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Raphael Pharmaceutical Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Raphael Pharmaceutical Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Raphael Pharmaceutical Inc. Competitors by Total Liabilities
The table below lists competitors of Raphael Pharmaceutical Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Holy Stone Healthcare Co., Ltd.
TWO:4194
|
Taiwan | NT$37.68 Million |
|
FINEDIGITAL Inc
KQ:038950
|
Korea | ₩11.17 Billion |
|
Amigo Technology Inc.
TWO:6241
|
Taiwan | NT$241.95 Million |
|
Graines Voltz S.A
PA:GRVO
|
France | €98.87 Million |
|
Solidion Technology Inc.
NASDAQ:STI
|
USA | $22.49 Million |
|
Elsoft Research Bhd
KLSE:0090
|
Malaysia | RM5.75 Million |
|
Green Bridge Metals Corporation
F:J48
|
Germany | €1.05 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Raphael Pharmaceutical Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 181.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Raphael Pharmaceutical Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Raphael Pharmaceutical Inc. (2020–2024)
The table below shows the annual total liabilities of Raphael Pharmaceutical Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $769.00K | +482.58% |
| 2023-12-31 | $132.00K | -41.85% |
| 2022-12-31 | $227.00K | -22.79% |
| 2021-12-31 | $294.00K | -19.67% |
| 2020-12-31 | $366.00K | -- |